PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2139402

Who joins the BDA?

N Robinson
View original source ↗Export metadata ↓

Abstract

A comparison of demographic and clinical characteristics was made between a random sample of members and non-members of the British Diabetic Association (BDA) of working age (17-65 years) who responded to a questionnaire concerning their employment. There were large regional variations in BDA membership, but overall 27% of responders were BDA members. Of the responders, BDA members were more likely to be women than men (30 vs 25%, p = 0.04) and under rather than over the age of 36 years (38 vs 21%, p less than 0.001). A greater proportion of insulin-treated patients with diabetes were BDA members compared with patients who were not treated with insulin (37 vs 13%, p less than 0.001). Unemployment was significantly less amongst BDA members compared with non-members (12 vs 20%, p less than 0.001). Membership decreased with decreasing social status, with significantly more house-owners being BDA members compared with those living in rented accommodation (31 vs 23%, p less than 0.001).

Explore related subjects

Diabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansPrevalenceSocieties, ScientificSurveys and QuestionnairesUnited KingdomJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N Robinson. Who joins the BDA?. https://doi.org/10.1111/j.1464-5491.1990.tb01384.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues.

The purification of animal insulin preparations and the use of human recombinant insulin have markedly reduced the incidence but not completely suppressed the occurrence of insulin allergy manifestations. Advances in technologies concerning the mode of delivery of insulin, i.e. continuous subcutaneous insulin infusion (CSII), and the use of insulin analogues, resulting from the alteration in the amino acid sequence of the native insulin molecule, may influence the immunogenicity and antigenicity of native insulin. Instead of increasing allergy reactions, CSII has been reported to represent a successful alternative treatment in diabetic patients presenting local or generalized allergy to insulin or other components (zinc, protamine) of conventional treatment. Most recent reports concern CSII-treated patients using short-acting insulin analogues (essentially insulin lispro), although the precise role of these insulin analogues remains unclear as allergy to them has also been described. Finally, data on antigenicity and immunogenicity of long-acting insulin analogues (glargine, detemir), which may mimic the basal insulin delivery with CSII, remain scarce at present.

Diabetes Mellitus↗
PubMed2007

Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease.

Insulin deficiency is known to be associated with a state of increased muscle protein breakdown; this process is mediated by the ubiquitin-proteasome pathway. Convincing in vitro data are further supported by extensive studies in humans with insulin deprivation and are further substantiated by reversal of muscle protein breakdown with insulin treatment. In patients with end-stage renal disease (ESRD) and diabetes mellitus (DM), muscle protein breakdown is enhanced in both acute and chronic conditions. Recent data also point to the potential protein catabolic effects of insulin resistance combined with insulin deficiency. Because ESRD is associated with a state of insulin resistance, uremic muscle wasting may also be mediated by this pathway.

Diabetes Mellitus↗